AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34650303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton (Nr‐CWS) combined with normal saline
Number of subjects: 60
Study 34650303 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo without Nr‐CWS combined with normal saline
Number of subjects: 60
Study 32709784 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual eyelid retraction
Number of subjects: 99
Study 32709784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton-tipped applicator (CTA)
Number of subjects: 99
Study 32709784 — intervention group
Group type: COMPARATOR
Intervention: Speculum
Number of subjects: 99
Study 35802640 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of nearshore, moored fish aggregating devices (FADs) to improve catch rates with existing fishing gears.
Number of subjects: 0
Study 35802640 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and behaviour change (SBC) activity to promote fish consumption.
Number of subjects: 0
Study 35802640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (FADs and SBC activities).
Number of subjects: 0
Study 35802640 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment (control group).
Number of subjects: 0
Study 34050932 — intervention group
Group type: EXPERIMENTAL
Intervention: FIASMA medication
Number of subjects: 2846
Study 34050932 — intervention group
Group type: COMPARATOR
Intervention: No FIASMA medication
Number of subjects: 2846
Study 32079835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic tattoos (colors yellow and green)
Number of subjects: 369
Study 32079835 — intervention group
Group type: COMPARATOR
Intervention: No cosmetic tattoos (control group)
Number of subjects: 369
Study 35314185 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal experimental group (MMG)
Number of subjects: 47
Study 35314185 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control (SOC)
Number of subjects: 47
Study 32790036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent music reward therapy (8 sessions)
Number of subjects: 60
Study 32790036 — intervention group
Group type: COMPARATOR
Intervention: Control condition (gaze-noncontingent music, 8 sessions)
Number of subjects: 60
Study 35294545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to temozolomide treatment
Number of subjects: 122
Study 35294545 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide treatment alone (control)
Number of subjects: 122
Study 33952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention to share knowledge with teachers about CVI.
Number of subjects: 0
Study 33952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention implementation and knowledge of CVI.
Number of subjects: 0
Study 33952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to visual clutter in classrooms.
Number of subjects: 0
Study 33952549 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to school special educational needs and disability (SEND) policies.
Number of subjects: 0
Study 35861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily for 104 weeks
Number of subjects: 308
Study 35861630 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 104 weeks
Number of subjects: 308
Study 33714843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter preserving operation (SPO)
Number of subjects: 76
Study 33714843 — intervention group
Group type: COMPARATOR
Intervention: Abdominoperineal resection (APR)
Number of subjects: 76
Study 33714843 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 76
Study 33714843 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of tumor invasion
Number of subjects: 76
Study 33714843 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial margin status
Number of subjects: 76
Study 32402702 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine noninvasive stress testing (exercise electrocardiography, nuclear stress imaging, or stress echocardiography) at 12 months post-PCI
Number of subjects: 1700
Study 32402702 — intervention group
Group type: COMPARATOR
Intervention: Standard-care without routine testing
Number of subjects: 1700
Study 35072852 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month capecitabine regimen
Number of subjects: 0
Study 35072852 — intervention group
Group type: COMPARATOR
Intervention: 6-month regimen
Number of subjects: 0
Study 34880344 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using an Oculus Quest® helmet
Number of subjects: 21
Study 34880344 — intervention group
Group type: COMPARATOR
Intervention: Topical Anesthesia (TA) 20% benzocaine
Number of subjects: 21
Study 35842736 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32928582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, predominantly dairy-based breakfast meal
Number of subjects: 19
Study 32928582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, predominantly soy-based breakfast meal
Number of subjects: 19
Study 32928582 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-MetS)
Number of subjects: 19
Study 32826737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 431
Study 32826737 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 431
Study 35461239 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter program (12-week duration)
Number of subjects: 235
Study 33693546 — intervention group
Group type: EXPERIMENTAL
Intervention: Omixer - a Bioconductor package for sample randomization in omics studies
Number of subjects: 0
Study 32247654 — intervention group
Group type: EXPERIMENTAL
Intervention: ErgoActive group (n=15) received 8 weeks of training with leap motion controller‐based virtual reality games, 1 day per week for 30min
Number of subjects: 30
Study 32247654 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 30
Study 32978622 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed bivariate effect modification analysis method
Number of subjects: 0
Study 32978622 — intervention group
Group type: COMPARATOR
Intervention: Existing methods for bivariate effect modification analysis
Number of subjects: 0
Study 33933732 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formula including 4 proteins (P4)
Number of subjects: 20
Study 33933732 — intervention group
Group type: COMPARATOR
Intervention: Casein-dominant formula (Cas)
Number of subjects: 20
Study 32607949 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 50
Study 32607949 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study 34990777 — intervention group
Group type: EXPERIMENTAL
Intervention: 64Gy salvage RT
Number of subjects: 344
Study 34990777 — intervention group
Group type: EXPERIMENTAL
Intervention: 70Gy salvage RT
Number of subjects: 344
Study 34990777 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 344
Study 32942255 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Stroke Kayak Test (SSKT)
Number of subjects: 21
Study 32942255 — intervention group
Group type: COMPARATOR
Intervention: Bench Press
Number of subjects: 21
Study 32942255 — intervention group
Group type: COMPARATOR
Intervention: Prone Bench Pull
Number of subjects: 21
Study 32942255 — intervention group
Group type: EXPERIMENTAL
Intervention: F-V slope
Number of subjects: 21
Study 35606238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of the vaccine from the pictured doctor (Poster M)
Number of subjects: 0
Study 35606238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement with information about COVID-19 risk (Poster M + R)
Number of subjects: 0
Study 35606238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement with information about risk and appeal to get vaccinated to protect friends and family (Poster M + R + F)
Number of subjects: 0
Study 35606238 — intervention group
Group type: COMPARATOR
Intervention: Control message (Control Poster)
Number of subjects: 0
Study 34264698 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP program
Number of subjects: 119
Study 34264698 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 119
Study 35506965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk fill resin composite (Filtek Bulk Fill Posterior Restorative)
Number of subjects: 62
Study 35506965 — intervention group
Group type: COMPARATOR
Intervention: Resin‐modified glass‐ionomer cement (Vitremer)
Number of subjects: 62
Study 32442634 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-plate fixation
Number of subjects: 39
Study 32442634 — intervention group
Group type: COMPARATOR
Intervention: Two-plate fixation
Number of subjects: 39
Study 33618991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-jet dissection
Number of subjects: 68
Study 33618991 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic surgical aspirator
Number of subjects: 68
Study 35723127 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-guided deep breathing (DB) integrated into conventional physiotherapy (CP)
Number of subjects: 30
Study 35723127 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 30
Study 33427091 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 1 anti-tubercular treatment with additional prednisolone
Number of subjects: 54
Study 33427091 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-tubercular treatment alone (Control)
Number of subjects: 54
Study 35254246 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist model (behavioral health counselor‐delivered brief intervention)
Number of subjects: 0
Study 35254246 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist model (primary care provider‐delivered brief intervention)
Number of subjects: 0
Study 34112063 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy for ICs (ERT‐C)
Number of subjects: 65
Study 34112063 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework completion
Number of subjects: 65
Study 34112063 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentering
Number of subjects: 65
Study 32832985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention ('Step by Step')
Number of subjects: 115
Study 32832985 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard geriatric inpatient rehabilitation)
Number of subjects: 115
Study 35647184 — intervention group
Group type: EXPERIMENTAL
Intervention: High Power Laser Therapy (HPLT) for 3 weeks
Number of subjects: 36
Study 35647184 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy program (ultrasound therapy, moist heat pack, and home exercises) for 3 weeks
Number of subjects: 36
Study 35647184 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HPLT vs Conventional physiotherapy
Number of subjects: 36
Study 34153870 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for detecting early-stage ONFH lesions on MRI
Number of subjects: 110
Study 32791321 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (alcohol vs. distress, guilt vs. no guilt)
Number of subjects: 600
Study 32791321 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 600
Study 32791321 — intervention group
Group type: COMPARATOR
Intervention: Personalized feedback
Number of subjects: 600
Study 34697254 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAYFun Program (12-week games-based program delivered by exercise physiologists)
Number of subjects: 50
Study 34697254 — intervention group
Group type: COMPARATOR
Intervention: Usual preschool curriculum (control group)
Number of subjects: 50
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: Local irradiation
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cytokines
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule inhibitors
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccines
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic viruses
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR agonists
Number of subjects: 0
Study 34248142 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM (specialized proresolving mediators)
Number of subjects: 0
Study 32517674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevail Staff intervention (stigma reduction and psychoeducation about low intensity psychological interventions)
Number of subjects: 960
Study 32517674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevail Managers programme (communication skills, problem formulation, and problem-solving skills)
Number of subjects: 960
Study 32517674 — intervention group
Group type: COMPARATOR
Intervention: Control (employment as usual)
Number of subjects: 960
Study 35470483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethine gel
Number of subjects: 58
Study 32286233 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-Based Learning and Assessment System (CBLAS)
Number of subjects: 117
Study 34509404 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 590
Study 34509404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 34375135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) for 48 hours
Number of subjects: 114
Study 34375135 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) for 24 hours
Number of subjects: 114
Study 34375135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged TTM (48 hours)
Number of subjects: 114
Study 34375135 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP and NT-proBNP levels at 24 hours
Number of subjects: 114
Study 33933848 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (SM) plus Interferon beta (IFN‐β)
Number of subjects: 0
Study 35844038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 80 mg
Number of subjects: 36
Study 35844038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Number of subjects: 36
Study 35844038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Number of subjects: 36
Study 35844038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept (all doses)
Number of subjects: 36
Study 32881723 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-talker speech masker
Number of subjects: 2
Study 32881723 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-shaped noise masker
Number of subjects: 2
Study 32881723 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 2
Study 35503342 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive laminectomy
Number of subjects: 94
Study 35503342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion
Number of subjects: 94
Study 35503342 — intervention group
Group type: COMPARATOR
Intervention: Lumbar decompression alone
Number of subjects: 94
Study 35503342 — intervention group
Group type: COMPARATOR
Intervention: Decompression plus fusion
Number of subjects: 94
Study 36482603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise program combined with a cognitive task
Number of subjects: 0
Study 36482603 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34377197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and dexmedetomidine combination
Number of subjects: 162
Study 34377197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 162
Study 34377197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 162
Study 32812388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg diluted to 5 ml with 0.9% saline)
Number of subjects: 330
Study 32812388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of 0.9% saline)
Number of subjects: 330
Study 32812388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg)
Number of subjects: 330
Study 34252374 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant CapOx (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral capecitabine 1000 mg/m2 twice a day)
Number of subjects: 1022
Study 34252374 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day)
Number of subjects: 1022
Study 34252374 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day for three cycles preoperatively and five cycles postoperatively followed by three cycles of S-1 monotherapy)
Number of subjects: 1022
Study 34119628 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 105
Study 34119628 — intervention group
Group type: COMPARATOR
Intervention: Control group without statin treatment
Number of subjects: 105
Study 34119628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 34119628 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina (SA)
Number of subjects: 105
Study 34119628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS)
Number of subjects: 105
Study 34365900 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/N95 face mask
Number of subjects: 0
Study 33751401 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI301 plus CHOP (375 mg/m2)
Number of subjects: 419
Study 33751401 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus CHOP (375 mg/m2)
Number of subjects: 419
Study 33751401 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI301 plus CHOP
Number of subjects: 419
Study 33751401 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus CHOP
Number of subjects: 419
Study 33064780 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of days alcohol abstinent
Number of subjects: 313
Study 34708255 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg lysergic acid diethylamide (LSD)
Number of subjects: 24
Study 34708255 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 24
Study 34782842 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Empowerment Model
Number of subjects: 80
Study 34782842 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 32683732 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy in addition to standard dermatology treatment
Number of subjects: 60
Study 32683732 — intervention group
Group type: COMPARATOR
Intervention: Standard dermatology treatment only (Control)
Number of subjects: 60
Study 32683732 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 60
Study 33722518 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A treatment in addition to oral medication (B+ group)
Number of subjects: 60
Study 33722518 — intervention group
Group type: COMPARATOR
Intervention: Oral medication only (B- group)
Number of subjects: 60
Study 33481179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate 1 mL/kg/day for 1 month
Number of subjects: 100
Study 33481179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33481179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate
Number of subjects: 100
Study 35429739 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive psychosocial training program and 10-min daily exercise (36 days total; n = 23; depressed at baseline n = 14)
Number of subjects: 45
Study 35429739 — intervention group
Group type: COMPARATOR
Intervention: Gratitude journaling control group (36 days total; n = 22; depressed at baseline n = 13)
Number of subjects: 45
Study 35429739 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive psychosocial training program
Number of subjects: 45
Study 35429739 — intervention group
Group type: COMPARATOR
Intervention: Gratitude journaling control group
Number of subjects: 45
Study 33771952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence/accommodative therapy
Number of subjects: 310
Study 33771952 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 310
Study 36260859 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (25-μg injections, two doses, administered 28 days apart)
Number of subjects: 4802
Study 36260859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4802
Study 36260859 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (25-μg injections, two doses)
Number of subjects: 4802
Study 34767575 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioural therapy (bCBT)
Number of subjects: 114
Study 34767575 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioural therapy (ftfCBT)
Number of subjects: 114
Study 33564849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 0
Study 33564849 — intervention group
Group type: COMPARATOR
Intervention: Sham conditions
Number of subjects: 0
Study 33564849 — intervention group
Group type: COMPARATOR
Intervention: Placebo effects
Number of subjects: 0
Study 33564849 — intervention group
Group type: COMPARATOR
Intervention: Heterogeneity in symptoms and treatments
Number of subjects: 0
Study 33564849 — intervention group
Group type: COMPARATOR
Intervention: Tangential medical issues
Number of subjects: 0
Study 34231956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional freehand dental implant placement
Number of subjects: 90
Study 34231956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic computer-aided implant surgery (CAIS)
Number of subjects: 90
Study 34231956 — intervention group
Group type: EXPERIMENTAL
Intervention: Static computer-aided implant surgery (CAIS)
Number of subjects: 90